For investors looking for expansion without high cost, the "Growth at a Reasonable Price" (GARP) method presents a middle path. It tries to find companies with good expansion prospects that are not valued at a high level, frequently by looking for solid growth measures paired with acceptable valuation figures. This process helps sidestep the risks of pursuing popular, costly stocks while focusing on firms with good fundamental progress. One stock recently found using this type of value growth screen is Harrow Inc (NASDAQ:HROW), a pharmaceutical firm located in Nashville.
Good Growth Path
The main attraction of Harrow for a GARP method is its notable growth history, which is a key requirement in the screening steps. A firm needs to display increasing or maintained expansion to warrant investment, and HROW's numbers are persuasive. Based on the fundamental analysis report, the company's sales increased by 36.41% over the last year, with a long-term yearly growth rate close to 41%. More notably, earnings per share (EPS) rose by over 104% in the past year. The future view is even more positive, with analysts predicting average yearly EPS growth of 216.53% and sales growth of 33.73% in the next few years. This effective mix of good past results and outstanding forecasted growth creates the basis of its attraction for investors focused on expansion.
An Acceptable Valuation
While expansion is necessary, paying a very high price for it can reduce future gains. This is where the valuation check turns important. Harrow's valuation shows a varied but finally acceptable view when examined:
- Standard Measures: The stock's Price-to-Earnings (P/E) ratio seems very elevated initially. However, this is viewed well against its pharmaceutical industry counterparts, with HROW being valued lower than over 76% of the sector. Its Price-to-Free Cash Flow ratio is also appealing, ranking lower than 80% of industry rivals.
- Future-Oriented and Growth-Conscious Figures: The valuation view gets better notably when thinking about future profits and growth. The forward P/E ratio matches the wider S&P 500 average. Most significantly, the low PEG ratio—which modifies the P/E for expected profit growth—suggests the stock's present price may be a fair exchange for its high growth possibility.
This detailed valuation picture, where the company is not low-cost on a fixed basis but seems acceptably priced compared to its growth, is exactly what value growth screens are made to find.
Supporting Basics: Earnings and Financial Condition
A simple growth-and-value screen can occasionally point out weak companies. So, confirming acceptable basic financial strength and earnings is a central idea of a careful GARP method. Harrow's results in these areas give a supportive, though not outstanding, setting.
- Earnings: The company receives a neutral earnings score. Its margins are a definite positive, with both Gross Margin (75.05%) and Operating Margin (11.21%) beating over 82% of the pharmaceutical industry. Its Return on Invested Capital (ROIC) of 7.95% is also with the top in its field. These figures imply the company is not only increasing revenue, but is doing so with an effective operational framework.
- Financial Condition: The financial condition score is also neutral. Good points contain a sound Altman-Z score showing low short-term bankruptcy danger and acceptable Current and Quick ratios indicating good immediate liquidity. Investors should be aware, though, of a somewhat high Debt-to-Equity ratio, which suggests a notable dependence on debt funding, a element to watch as interest rates stay high.
Summary and Additional Study
Harrow Inc shows the kind of possibility a value growth screen intends to find: a company with clearly good and forecasted growth, trading at a valuation that can be explained by that growth path, and backed by sufficient earnings and financial condition. It is not free from its dangers, specifically related to its debt amount and the fact that net income has been negative in recent years, but the main growth story and acceptable price make it a subject for more investigation.
For investors wanting to examine other stocks that match this "Growth at a Reasonable Price" description, you can find more outcomes by using the Affordable Growth stock screener.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation, or an offer to buy or sell any security. Investing involves risk, including the potential loss of principal. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.